Cargando…
ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer
Autores principales: | Petit, Robert G, Basu, Partha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990983/ http://dx.doi.org/10.1186/2051-1426-1-S1-P231 |
Ejemplares similares
-
ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
por: Petit, Robert G, et al.
Publicado: (2014) -
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
por: Basu, Partha, et al.
Publicado: (2018) -
Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy
por: Molli, Poonam, et al.
Publicado: (2013) -
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
por: Miles, Brett A., et al.
Publicado: (2017) -
Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
por: Cohen, Ezra EW, et al.
Publicado: (2015)